During the past decade, Palm Research Center conducted 58 clinical trials. In the 10-year time frame, 58 clinical trials started and 32 clinical trials were completed, i.e. on average, 55.2% percent of trials that started reached the finish line to date. In the past 5 years, 28 clinical trials started and 25 clinical trials were completed. i.e. 89.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Palm Research Center" #1 sponsor was "Eli Lilly and Company" with 20 trials, followed by "Boehringer Ingelheim" with 6 trials sponsored, "Ionis Pharmaceuticals, Inc." with 5 trials sponsored, "Allergan" with 4 trials sponsored and "Amgen" with 4 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Palm Research Center" #1 collaborator was "Eli Lilly and Company" with 5 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Syneos Health" with 2 trials as a collaborator, "CS Lifescience" with 1 trials as a collaborator and "Clinical Trial Mentors" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Palm Research Center" are "Diabetes Mellitus, Type 2" (9 trials), "Type 2 Diabetes" (7 trials), "Type 2 Diabetes Mellitus" (7 trials), "Acromegaly" (5 trials) and "Diabetes Mellitus, Type 1" (5 trials). Many other conditions were trialed in "Palm Research Center" in a lesser frequency.

Most popular intervention types in "Palm Research Center" are "Drug" (53 trials), "Device" (6 trials), "Other" (4 trials), "Biological" (3 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (23 trials), "Insulin Degludec" (7 trials), "Tirzepatide" (7 trials), "Empagliflozin" (4 trials) and "Insulin Glargine" (4 trials). Other intervention names were less common.

The vast majority of trials in "Palm Research Center" are 63 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Palm Research Center". undefined are not yet recruiting, 8 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 34 completed trials in Palm Research Center, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Palm Research Center, 0 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 43 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".